Neumora Therapeutics, Inc. Overview
Pro stress-test →Neumora Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company employs a precision medicine approach leveraging translational, clinical, and computational tools to target unmet medical needs in CNS diseases with best-in-class pharmacology.
Strategic Profile
Pro stress-test →Neumora's competitive advantage lies in its multi-program pipeline targeting innovative mechanisms of action including kappa opioid receptor antagonism, vasopressin 1a receptor antagonism, and M4 positive allosteric modulation. Multiple clinical data readouts expected in 2026, including KOASTAL-2 and KOASTAL-3 trials, present significant value creation opportunities if successful.
Competitive Landscape
Pro stress-test →Neumora competes within the CNS drug development space against larger biotech and pharma companies targeting neuropsychiatric and neurodegenerative diseases. Key competitive advantages include novel mechanism targets (KOR, V1aR, M4 PAM) and precision medicine platform. Major competitors include established players like Eli Lilly, Biogen, and emerging biotech focused on Alzheimer's and psychiatric indications.
Industry Context
Neumora Therapeutics, Inc. operates in Biopharmaceutical - Clinical Stage CNS/Neuroscience.
Key facts
Founded: 2019 · Headquarters: Watertown, Massachusetts · Revenue: $0 · Market cap: $109.9M